Lipigon Pharmaceuticals AB

Lipigon Pharmaceuticals is a biology specialist company founded in 2010, developing novel therapies for patients with lipid disorders and other cardiometabolic risk factors. Currently, Lipigon is focusing on the discovery of small molecule activators of Lipoprotein lipase (LPL). Individuals with lowered activity of LPL have increased dyslipidemia associated with multiple metabolic abnormalities, and our lead product candidate is designed to lower elevated levels of TG, raise levels of HDL and improve other cardiometabolic risk factors.

 

Contact: Stefan Nilsson, CEO

Contact details
Blåkullevägen 23, SE-90752 Umeå, Sweden
Phone: +46770 - 578 176